Palvella Therapeutics (PVLA) EBIT (2016 - 2024)
Historic EBIT for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.4 million.
- Palvella Therapeutics' EBIT fell 13261.62% to -$4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$14.1 million, marking a year-over-year decrease of 1875.47%. This contributed to the annual value of -$14.1 million for FY2024, which is 1875.47% down from last year.
- As of Q4 2024, Palvella Therapeutics' EBIT stood at -$4.4 million, which was down 13261.62% from -$5.1 million recorded in Q3 2024.
- Palvella Therapeutics' 5-year EBIT high stood at $13.4 million for Q4 2023, and its period low was -$19.0 million during Q3 2021.
- For the 5-year period, Palvella Therapeutics' EBIT averaged around -$7.8 million, with its median value being -$9.2 million (2021).
- As far as peak fluctuations go, Palvella Therapeutics' EBIT tumbled by 83315.79% in 2020, and later soared by 21620.8% in 2023.
- Quarter analysis of 5 years shows Palvella Therapeutics' EBIT stood at -$12.4 million in 2020, then increased by 11.38% to -$11.0 million in 2021, then dropped by 4.73% to -$11.5 million in 2022, then surged by 216.21% to $13.4 million in 2023, then tumbled by 132.62% to -$4.4 million in 2024.
- Its last three reported values are -$4.4 million in Q4 2024, -$5.1 million for Q3 2024, and -$2.9 million during Q2 2024.